<a href="https://www.fiercebiotech.com/biotech/beone-shelves-5-cancer-programs-halts-phase-2-rheumatoid-arthritis-trial" hreflang="en">BeOne shelves 5 cancer programs, halts phase 2 rheumatoid arthritis trial</a>
BeOne Medicines has discontinued five early-stage cancer programs and halted a phase 2 trial for rheumatoid arthritis due to new data, although they plan to continue pursuing related targets through other promising assets in their pipeline. The decision reflects a strategic review of their development criteria, despite the ongoing interest in the RAS field and recent investments in new preclinical candidates.
BeOne Medicines' decision to discontinue several early-stage cancer programs and a phase 2 rheumatoid arthritis trial highlights the importance of agile portfolio management in biotech, driven by emerging data and market dynamics. For professionals in healthtech and biotech, this underscores the potential for strategic reallocation of resources towards promising multi-modality approaches and highlights the red-hot potential of RAS inhibitors, as exemplified by recent developments with Revolution Medicines and AbbVie.